Patents by Inventor Chantale Bernatchez

Chantale Bernatchez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES AND USE THEREOF
    Publication number: 20230106973
    Abstract: Provided herein are methods for the activation and expansion of genetically-modified Tcells, such as tumor infiltrating lymphocytes. In some cases, cells of the embodiments can be used for the therapeutic treatment of human diseases, such as cancer.
    Type: Application
    Filed: February 16, 2021
    Publication date: April 6, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Marie-Andrée FORGET, Chantale BERNATCHEZ, Cara HAYMAKER, Michael A. CURRAN, Patrick HWU, Cassian YEE
  • HUMAN 4-1BB AGONIST ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230092390
    Abstract: Isolated or recombinant monoclonal antibodies that bind to 4-1BB are provided. In son cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Application
    Filed: February 17, 2021
    Publication date: March 23, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Michael A. CURRAN, Renee CHIN, Marie-Andrée FORGET, Chantale BERNATCHEZ
  • TLR9 MODULATORS FOR TREATING CANCER
    Publication number: 20210340544
    Abstract: The present disclosure relates to methods for treating cancer in patients having low expression of MHC Class I genes, and in patients having increased serum levels of PD-L2 by administration of a TLR9 agonist.
    Type: Application
    Filed: October 18, 2019
    Publication date: November 4, 2021
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Cara HAYMAKER, Chantale BERNATCHEZ, Adi DIAB, Srinivas CHUNDURU
  • B and T lymphocyte attenuator marker for use in adoptive T-cell therapy
    Patent number: 9512401
    Abstract: BTLA-positive (“BTLA+”) lymphocyte signaling drives T cells and kills tumors. BTLA functions as a positive modulator of anti-tumor (anti-melanoma) T cell responses, The BTLA+ T cell responds against tumor or cancer cells, and, in cancer patients respond better to IL-2 than BTLA-negative cells. Hence, the BTLA-positive T cell in cancers is a positive marker for selection of enriched anti-tumor-cancer reactive T cells and can be used or applied for adoptive T-cell therapy or for therapeutic purposes.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: December 6, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: Laszlo Radvanyi, Patrick Hwu, Chantale Bernatchez
  • B AND T LYMPHOCYTE ATTENUATOR MARKER FOR USE IN ADOPTIVE T-CELL THERAPY
    Publication number: 20130302300
    Abstract: BTLA-positive (“BTLA+”) lymphocyte signaling drives T cells and kills tumors. BTLA functions as a positive modulator of anti-tumor (anti-melanoma) T cell responses, The BTLA+ T cell responds against tumor or cancer cells, and, in cancer patients respond better to IL-2 than BTLA-negative cells. Hence, the BTLA-positive T cell in cancers is a positive marker for selection of enriched anti-tumor-cancer reactive T cells and can be used or applied for adoptive T-cell therapy or for therapeutic purposes.
    Type: Application
    Filed: September 30, 2011
    Publication date: November 14, 2013
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laszlo Radvanyi, Patrick Hwu, Chantale Bernatchez